Insider Transactions in Q1 2025 at Regulus Therapeutics Inc. (RGLS)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 14
2025
|
Crispina Calsada Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,088
-10.06%
|
$5,088
$1.26 P/Share
|
|
Jan 14
2025
|
Joseph P Hagan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,764
-5.29%
|
$11,764
$1.26 P/Share
|
|
Jan 14
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Open market or private sale
|
Direct |
5,088
-9.31%
|
$5,088
$1.26 P/Share
|
|
Jan 13
2025
|
Preston Klassen President & Head of R & D |
SELL
Open market or private sale
|
Direct |
31,445
-46.59%
|
$31,445
$1.26 P/Share
|
|
Jan 13
2025
|
Crispina Calsada Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
38,716
-43.36%
|
$38,716
$1.26 P/Share
|
|
Jan 13
2025
|
Joseph P Hagan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
115,290
-34.12%
|
$115,290
$1.26 P/Share
|
|
Jan 13
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Open market or private sale
|
Direct |
38,547
-41.37%
|
$38,547
$1.26 P/Share
|
|
Jan 09
2025
|
Preston Klassen President & Head of R & D |
BUY
Grant, award, or other acquisition
|
Direct |
67,500
+40.38%
|
$67,500
$1.33 P/Share
|
|
Jan 09
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
84,125
+31.31%
|
$84,125
$1.33 P/Share
|
|
Jan 09
2025
|
Crispina Calsada Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
83,500
+33.42%
|
$83,500
$1.33 P/Share
|
|
Jan 09
2025
|
Joseph P Hagan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
280,750
+29.87%
|
$280,750
$1.33 P/Share
|